Table 1 Demographics and clinical characteristics of the study population
Parameters | Healthy control (n = 56) | Resolved HBV (n = 14) | Chronic hepatitis B (n = 58) | Advanced liver disease (n = 34) | P value |
|---|---|---|---|---|---|
Age (years) | 28 (24–36) | 57 (53–65) | 51 (42–59) | 62 (56–67) |  < 0.0001abcf |
Sex (male) | 18 (32) | 7 (50) | 38 (66) | 28 (82) |  < 0.0001 |
BMI (kg/m2) |  | 23.3 (22.1–25.8) | 23.5 (20.6–27.0) | 24.2 (20.8–26.4) | 0.9131 |
HBsAg positive |  | 0 (0) | 58 (100) | 33 (97.1) |  < 0.0001 |
HBeAg positive | Â | 0 (0) | 19 (32.8) | 5 (14.7) | 0.0153 |
ALT (U/L) | 6 (5–10) | 12 (10–20) | 29.5 (18–76) | 25.5 (18–42) |  < 0.0001abcde |
AST (U/L) | 12.5 (9–15) | 18.5 (17–25) | 27 (19–57) | 28 (18–54) |  < 0.0001abc |
BUN (mg/dL) | 10.3 (8.9–12.5) | 14.4 (10.3–15.7) | 13.5 (10.1–15.9) | 16.3 (13.1–18.8) |  < 0.0001bcf |
CRE (mg/dL) | 0.6 (0.5–0.7) | 0.7 (0.7–0.8) | 0.8 (0.7–0.9) | 0.9 (0.8–1) |  < 0.0001abc |
GLU-AC (mg/dL) | 73.5 (67–80) | 98 (89–115) | 91 (86–96) | 103 (90–141) |  < 0.0001abc |
Platelet count (109/L) |  | 230 (211–245) | 215 (170–249) | 180 (113–207) | 0.0019ef |
T-CHO (mg/dL) |  | 180 (159–225) | 191 (146–215) | 178 (142–199) | 0.5517 |
HDL (mg/dL) |  | 42 (38–62) | 51 (42–56) | 47 (39–52) | 0.8869 |
LDL (mg/dL) |  | 105 (89–124) | 118 (83–142) | 109 (98–132) | 0.7194 |
TG (mg/dL) |  | 145 (113–193) | 84 (74–133) | 103 (78–127) | 0.1166 |